查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1503439

到 2030 年核准药物测试 (LDT) 市场预测：按产品、测试类型、应用、最终用户和地区进行的全球分析

Laboratory-Developed Testing Market Forecasts to 2030 - Global Analysis By Product (Mass Spectrometry, Microarrays and Next-Generation Sequencing ), Test Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球核准药物检测 (LDT) 市场规模为 58.6 亿美元，预计到 2030 年将达到 101.6 亿美元，预测期内复合年增长率为 9.6%。

核准药物测试 (LDT) 是在临床或研究环境中的单一实验室内创建、检验和执行的诊断测试。与商业化测试不同，LDT 通常旨在满足特定实验室或患者群体的特定需求。 LDT 的范围从简单的测定到复杂的分子测试，为疾病、遗传倾向和治疗方法提供了宝贵的见解。 LDT 在促进个人化医疗和缩小诊断能力差距方面发挥着重要作用。

根据世界卫生组织 (WHO) 的数据，癌症已成为 183 个国家中 112 个国家 70 岁以上人口的第一或第二大死因，并已成为其他 23 个国家的第三或第四大死因。

增加与遗传健康风险相关的产品供应

随着基因检测变得越来越普遍，人们对全面了解健康风险的需求也越来越大。这正在推动非核准测试（LDT）市场产品阵容的扩大。公司正在扩大其产品组合，包括评估更广泛的遗传健康风险的测试，以满足消费者的多样化需求。这些产品包括各种疾病易感性、药物基因组学、血统追踪等测试。透过提供多样化的产品，LDT 提供者旨在满足医疗保健专业人员和消费者不断变化的需求，同时满足人们对个人化医疗和预防性医疗保健策略日益增长的兴趣。

严格规定

严格的监管对 LDT 市场构成了重大限制，影响了创新和市场准入。这些法规通常由 FDA 等监管机构执行，要求对 LDT 进行严格的验证和合规标准，从而增加了开发时间和成本。公司在复杂的监管途径中面临障碍，限制了他们快速引入新测试的能力。此外，不断变化的法规需要不断适应，进一步增加了合规性挑战。

个人化医疗的持续研究

对个人化药物的持续研究正在非核准测试（LDT）市场创造重大机会。随着基因组学和分子生物学的进步加速，个人化治疗越来越成为现实。这一趋势推动了对准确诊断工具的需求，并促使实验室在 LDT 方面进行创新，以实现个人化治疗策略。透过持续研究，LDT 可以增强其分析基因突变和生物标记的能力，以帮助定製药物治疗方案。这一演变与精准医疗的转变相吻合，并为 LDT 领域的成长和创新提供了一条充满希望​​的途径。

执行诊断测试时面临的业务障碍

进行诊断测试时常会出现行政障碍。这些障碍包括法规遵循的复杂性、验证和品管的资源有限以及不同实验室标准化程序的挑战。此外，试剂和设备的一致供应链管理也是一个问题。现有医疗保健系统和资料管理平台的互通性问题使营运环境更加复杂。

COVID-19 的影响：

COVID-19 的疫情对核准药物检测（LDT）市场产生了重大影响。随着对准确诊断测试的迫切需求，对LDT，特别是COVID-19检测套组的需求正在迅速增加。这种不断增长的需求导致了对 LDT 研发的投资增加，并加强了监管监督，以确保测试的准确性和可靠性。此外，疫情也刺激了 LDT 技术的创新，促进了更快、更灵敏、更扩充性的测试解决方案的开发。然而，供应链中断和监管挑战也阻碍了市场成长。

预计在预测期内重症加护行业将是最大的

由于多种因素，核准药物检测 (LDT) 市场的重症加护领域正在显着增长。医疗技术的进步推动了需求的成长，推动了更复杂的测试的开发，这些测试可以快速评估急诊患者的关键健康指标。慢性病的增加需要对重症患者进行频繁监测，并增加了对专门检测的需求。此外，COVID-19 大流行凸显了快速、准确诊断的重要性，进一步加速了 LDT 在重症加护中的采用。 LDT 提供的可自订性和灵活性使医疗保健专业人员能够根据特定患者的需求量身定制测试，从而增强临床决策。

预计遗传学在预测期内的复合年增长率最高

在核准药物检测（LDT）市场中，遗传学领域正在经历显着的成长。基因组研究的进展揭示了有关疾病机制和个人化医疗的新知识，增加了对基因检测的需求。此外，基因定序技术成本的下降使得医疗保健专业人员和患者更容易获得这些测试。此外，遗传疾病的日益普及以及人们对早期检测和预防重要性的认识不断增强，正在推动基因检测服务的采用。这些测试为疾病风险评估、诊断、治疗选择和监测提供了有价值的信息，使其对现代医疗保健至关重要。

占比最大的地区：

最近的趋势表明，欧洲的核准药物检测（LDT）市场正在经历显着成长。这种成长是由多种因素推动的，包括对个人化医疗和诊断的需求增加、实现更复杂测试的技术进步以及对医疗保健品质和效率的日益关注。此外，欧洲的支持性法规环境和强大的医疗保健基础设施促进了 LDT 的创新和投资。因此，该地区检测设施激增，为各种临床需求提供专门的检测服务。

复合年增长率最高的地区：

由于多种因素，北美核准药物检测（LDT）市场正在经历显着成长。对个人化医疗和精准诊断的需求不断增长正在推动 LDT 服务的扩展。此外，次世代定序和分子诊断等技术的进步正在扩大 LDT 产品的范围。该地区的监管灵活性也促进了创新并加速了 LDT 的采用。此外，COVID-19 的爆发凸显了非核准检测的重要性，进一步提振了市场。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球临床检测市场：按产品

  • 质谱
  • 微阵列
  • 聚合酵素链锁反应(PCR)
  • 次世代定序（NGS）

第六章全球核准药物测试（LDT）市场：依测试类型

  • 微生物
  • 免疫
  • 加护治疗
  • 临床生物化学
  • 血
    • 血球计数测试
    • 凝血和止血
    • 血红素测试
  • 分子诊断

第七章 全球核准药物测试（LDT）市场：依应用分类

  • 研究与发展（R&D）
  • 肿瘤学
  • 神经病学
  • 感染疾病
  • 遗传学
  • 自体免疫疾病
  • 商业服务

第八章 全球核准药物测试 (LDT) 市场：按最终用户分类

  • 专业诊断中心
  • 学术机构
  • 医院实验室
  • 临床研究所
  • 其他最终用户

第九章按地区分類的全球核准药物检测（LDT）市场

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Epic Sciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Genoptix, Inc.
  • Guardant Health
  • Illumina, Inc.
  • OPKO Health Inc.
  • Qiagen
  • Quidel Corporation
  • Rosetta Genomics Ltd.
  • Siemens Healthcare Private Limited
  • Sonic Healthcare Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: SMRC26610

According to Stratistics MRC, the Global Laboratory-Developed Testing Market is accounted for $5.86 billion in 2024 and is expected to reach $10.16 billion by 2030 growing at a CAGR of 9.6% during the forecast period. Laboratory-developed testing (LDT) refers to diagnostic tests created, validated, and performed within a single laboratory, often in clinical or research settings. Unlike commercially available tests, LDTs are typically designed to meet the specific needs of a particular laboratory or patient population. They can range from simple assays to complex molecular tests, providing valuable insights into diseases, genetic predispositions, and treatment options. LDTs play a crucial role in advancing personalized medicine and filling gaps in diagnostic capabilities.

According to the World Health Organization, cancer is the leading or second-leading cause of death for those over the age of 70 in 112 of 183 nations, and third or fourth in the other 23 countries.

Market Dynamics:

Driver:

Increasing product offerings related to genetic health risks

As genetic testing becomes more prevalent, there's a growing demand for comprehensive insights into health risks. This driver fuels the expansion of product offerings within the Laboratory-Developed Testing (LDT) market. Companies are broadening their portfolios to include tests that assess a wider range of genetic health risks, catering to diverse consumer needs. These offerings may encompass tests for predispositions to various diseases, pharmacogenomics, and ancestry tracing, among others. By diversifying their products, LDT providers aim to meet the evolving demands of healthcare professionals and consumers while also capitalizing on the increasing interest in personalized medicine and preventive healthcare strategies.

Restraint:

Stringent regulations

Stringent regulations pose significant restraints in the Laboratory Developed Testing (LDT) market, impacting innovation and market entry. These regulations, often enforced by regulatory bodies like the FDA, require rigorous validation and compliance standards for LDTs, increasing the time and cost of development. Companies face hurdles in navigating complex regulatory pathways, limiting their ability to introduce new tests swiftly. Moreover, the evolving nature of regulations necessitates continuous adaptation, further adding to compliance challenges.

Opportunity:

Continuous research on personalized medicines

Continuous research on personalized medicines presents a significant opportunity within the Laboratory Developed Testing (LDT) market. As advancements in genomics and molecular biology accelerate, tailored therapies become increasingly viable. This trend drives the demand for precise diagnostic tools, prompting laboratories to innovate LDTs for individualized treatment strategies. With ongoing research, LDTs can enhance their capabilities to analyze genetic variations and biomarkers, aiding in the customization of medication regimens. This evolution aligns with the shift towards precision medicine, offering a promising avenue for growth and innovation in the LDT sector.

Threat:

Operational barriers faced in conducting diagnostic tests

Operational barriers often arise when conducting diagnostic tests. These hurdles may include regulatory compliance complexities, limited resources for validation and quality control, and challenges in standardizing procedures across different laboratories. Additionally, ensuring consistent supply chain management for reagents and equipment can be problematic. Interoperability issues with existing healthcare systems and data management platforms further complicate the operational landscape.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the laboratory-developed testing (LDT) market. With the urgent need for accurate diagnostic testing, there has been a surge in demand for LDTs, particularly for COVID-19 testing kits. This heightened demand has led to increased investment in LDT research and development, as well as regulatory scrutiny to ensure test accuracy and reliability. Furthermore, the pandemic has spurred innovation in LDT technologies, driving the development of faster, more sensitive, and more scalable testing solutions. However, supply chain disruptions and regulatory challenges have also posed obstacles to market growth.

The critical care segment is expected to be the largest during the forecast period

The Critical Care segment within the Laboratory Developed Testing (LDT) market is experiencing notable growth due to several factors. Advancements in medical technology have enabled the development of more sophisticated tests that can rapidly assess critical health indicators in acutely ill patients, driving demand. The rising prevalence of chronic diseases necessitates frequent monitoring of patients in critical care settings, fueling the need for specialized tests. Additionally, the COVID-19 pandemic has underscored the importance of rapid and accurate diagnostics, further boosting the adoption of LDTs in critical care. The customization and flexibility offered by LDTs allow healthcare providers to tailor tests to specific patient needs, enhancing clinical decision-making.

The Genetics segment is expected to have the highest CAGR during the forecast period

In the Laboratory Developed Testing (LDT) market, the genetics segment is experiencing notable growth. Advances in genomic research have unveiled new insights into disease mechanisms and personalized medicine, driving demand for genetic testing. Moreover, the declining cost of genetic sequencing technologies has made such tests more accessible to healthcare providers and patients. Additionally, the increasing prevalence of genetic disorders and the growing awareness of the importance of early detection and prevention are fuelling the adoption of genetic testing services. These tests offer valuable information for disease risk assessment, diagnosis, treatment selection, and monitoring, making them integral to modern healthcare practices.

Region with largest share:

In recent years, Europe has experienced significant growth in the Laboratory-Developed Testing (LDT) market. This growth can be attributed to several factors, including increasing demand for personalized medicine and diagnostics, advancements in technology enabling more sophisticated testing methods, and a rising emphasis on healthcare quality and efficiency. Additionally, Europe's supportive regulatory environment and robust healthcare infrastructure have fostered innovation and investment in LDT. As a result, the region has witnessed a proliferation of laboratories offering specialized testing services, catering to diverse clinical needs.

Region with highest CAGR:

The Laboratory-Developed Testing (LDT) market in North America has witnessed substantial growth driven by several factors. Increased demand for personalized medicine and precision diagnostics has propelled the expansion of LDT services. Additionally, advancements in technology, such as next-generation sequencing and molecular diagnostics, have widened the scope of LDT offerings. Regulatory flexibility in the region has also fostered innovation and accelerated the adoption of LDTs. Moreover, the COVID-19 pandemic has highlighted the importance of diagnostic testing, further boosting the market.

Key players in the market

Some of the key players in Laboratory-Developed Testing market include Abbott Laboratories, Adaptive Biotechnologies, Bio-Rad Laboratories, Inc., Bruker Corporation, Epic Sciences, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Genoptix, Inc., Guardant Health, Illumina, Inc., OPKO Health Inc., Qiagen, Quidel Corporation, Rosetta Genomics Ltd., Siemens Healthcare Private Limited, Sonic Healthcare Ltd. and Thermo Fisher Scientific Inc.

Key Developments:

In June 2024, Bruker Corporation launches the new top-of-the-line timsTOF Ultra 2 system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new Spectronaut 19 software and the novel PreOmics ENRICHplus kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics.

In March 2024, Global healthcare leader Abbott has announced the launch of its innovative automation solutions, GLP systems Track, to support laboratories' high-volume needs. With this launch, Abbott aims to strike a balance between quality of care and efficient use of resources. Across different care settings, depending on laboratory size and patient pool, this automation solution can handle bulk test tubes per day.

Products Covered:

  • Mass Spectrometry
  • Microarrays
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)

Test Types Covered:

  • Microbiology
  • Immunology
  • Critical Care
  • Clinical Biochemistry
  • Haematology
  • Molecular Diagnostics

Applications Covered:

  • Research and Development (R&D)
  • Oncology
  • Neurology
  • Infectious Diseases
  • Genetics
  • Autoimmune Disorders
  • Commercial Service

End Users Covered:

  • Specialty Diagnostics Centers
  • Academic Institutes
  • Hospital Laboratories
  • Clinical Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Laboratory-Developed Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Mass Spectrometry
  • 5.3 Microarrays
  • 5.4 Polymerase Chain Reaction (PCR)
  • 5.5 Next-Generation Sequencing (NGS)

6 Global Laboratory-Developed Testing Market, By Test Type

  • 6.1 Introduction
  • 6.2 Microbiology
  • 6.3 Immunology
  • 6.4 Critical Care
  • 6.5 Clinical Biochemistry
  • 6.6 Haematology
    • 6.6.1 Blood Count Testing
    • 6.6.2 Coagulation and Hemostasis
    • 6.6.3 Hemoglobin Testing
  • 6.7 Molecular Diagnostics

7 Global Laboratory-Developed Testing Market, By Application

  • 7.1 Introduction
  • 7.2 Research and Development (R&D)
  • 7.3 Oncology
  • 7.4 Neurology
  • 7.5 Infectious Diseases
  • 7.6 Genetics
  • 7.7 Autoimmune Disorders
  • 7.8 Commercial Service

8 Global Laboratory-Developed Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Specialty Diagnostics Centers
  • 8.3 Academic Institutes
  • 8.4 Hospital Laboratories
  • 8.5 Clinical Research Organizations
  • 8.6 Other End Users

9 Global Laboratory-Developed Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 Adaptive Biotechnologies
  • 11.3 Bio-Rad Laboratories, Inc.
  • 11.4 Bruker Corporation
  • 11.5 Epic Sciences, Inc.
  • 11.6 Eurofins Scientific
  • 11.7 F. Hoffmann-La Roche Ltd
  • 11.8 Genoptix, Inc.
  • 11.9 Guardant Health
  • 11.10 Illumina, Inc.
  • 11.11 OPKO Health Inc.
  • 11.12 Qiagen
  • 11.13 Quidel Corporation
  • 11.14 Rosetta Genomics Ltd.
  • 11.15 Siemens Healthcare Private Limited
  • 11.16 Sonic Healthcare Ltd.
  • 11.17 Thermo Fisher Scientific Inc.

List of Tables

  • Table 1 Global Laboratory-Developed Testing Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Laboratory-Developed Testing Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Laboratory-Developed Testing Market Outlook, By Mass Spectrometry (2022-2030) ($MN)
  • Table 4 Global Laboratory-Developed Testing Market Outlook, By Microarrays (2022-2030) ($MN)
  • Table 5 Global Laboratory-Developed Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2022-2030) ($MN)
  • Table 6 Global Laboratory-Developed Testing Market Outlook, By Next-Generation Sequencing (NGS) (2022-2030) ($MN)
  • Table 7 Global Laboratory-Developed Testing Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 8 Global Laboratory-Developed Testing Market Outlook, By Microbiology (2022-2030) ($MN)
  • Table 9 Global Laboratory-Developed Testing Market Outlook, By Immunology (2022-2030) ($MN)
  • Table 10 Global Laboratory-Developed Testing Market Outlook, By Critical Care (2022-2030) ($MN)
  • Table 11 Global Laboratory-Developed Testing Market Outlook, By Clinical Biochemistry (2022-2030) ($MN)
  • Table 12 Global Laboratory-Developed Testing Market Outlook, By Haematology (2022-2030) ($MN)
  • Table 13 Global Laboratory-Developed Testing Market Outlook, By Blood Count Testing (2022-2030) ($MN)
  • Table 14 Global Laboratory-Developed Testing Market Outlook, By Coagulation and Hemostasis (2022-2030) ($MN)
  • Table 15 Global Laboratory-Developed Testing Market Outlook, By Hemoglobin Testing (2022-2030) ($MN)
  • Table 16 Global Laboratory-Developed Testing Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 17 Global Laboratory-Developed Testing Market Outlook, By Application (2022-2030) ($MN)
  • Table 18 Global Laboratory-Developed Testing Market Outlook, By Research and Development (R&D) (2022-2030) ($MN)
  • Table 19 Global Laboratory-Developed Testing Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 20 Global Laboratory-Developed Testing Market Outlook, By Neurology (2022-2030) ($MN)
  • Table 21 Global Laboratory-Developed Testing Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 22 Global Laboratory-Developed Testing Market Outlook, By Genetics (2022-2030) ($MN)
  • Table 23 Global Laboratory-Developed Testing Market Outlook, By Autoimmune Disorders (2022-2030) ($MN)
  • Table 24 Global Laboratory-Developed Testing Market Outlook, By Commercial Service (2022-2030) ($MN)
  • Table 25 Global Laboratory-Developed Testing Market Outlook, By End User (2022-2030) ($MN)
  • Table 26 Global Laboratory-Developed Testing Market Outlook, By Specialty Diagnostics Centers (2022-2030) ($MN)
  • Table 27 Global Laboratory-Developed Testing Market Outlook, By Academic Institutes (2022-2030) ($MN)
  • Table 28 Global Laboratory-Developed Testing Market Outlook, By Hospital Laboratories (2022-2030) ($MN)
  • Table 29 Global Laboratory-Developed Testing Market Outlook, By Clinical Research Organizations (2022-2030) ($MN)
  • Table 30 Global Laboratory-Developed Testing Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.